People · Operator
Named in public records as an officer, director or promoter · active 2019–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. | — | Biotechnology | Series D+ | $152.0M | $4.0B | 2021 |
| Progenity, Inc. | — | Biotechnology | Series C | $141.6M | $409.6M | 2019 |
Brian Kotzin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Kotzin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Cohen | 1 | 12 |
| Ian Clark | 1 | 5 |
| Ryan Jones | 1 | 5 |
| Harry Stylli | 1 | 3 |
| Steve Liapis | 1 | 3 |
| Jeffrey Alter | 1 | 3 |
| Peter Maag | 1 | 2 |
| Howard Slutsky | 1 | 2 |
| Sumit Aggarwal | 1 | 2 |
| Jeffrey Ferrell | 1 | 2 |
| Samuel Nussbaum | 1 | 2 |
| Karen Walker | 1 | 2 |
| James Chung | 1 | 2 |
| Lynne Powell | 1 | 1 |
| Paul Hawran | 1 | 1 |
| Eric d'Esparbes | 1 | 1 |
| Dan Spiegelman | 1 | 1 |
| Beth Spiegelman | 1 | 1 |
| Dominic Borie | 1 | 1 |
| John Bigalke | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.